Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice

Brianna L. Norton; Matthew J. Akiyama; Philippe J. Zamor; Alain H. Litwin

doi:10.1016/j.idc.2018.02.001

Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice

Brianna L. Norton, Matthew J. Akiyama, Philippe J. Zamor, Alain H. Litwin

Medicine

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.

Original language	English (US)
Pages (from-to)	347-370
Number of pages	24
Journal	Infectious disease clinics of North America
Volume	32
Issue number	2
DOIs	https://doi.org/10.1016/j.idc.2018.02.001
State	Published - Jun 2018

Keywords

Best practice
Direct acting antivirals
Drug-drug interactions
Hepatitis C virus
Opioid agonist therapy

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.idc.2018.02.001

Cite this

@article{4ce18e16720645c8ac954d1dae55c244,

title = "Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice",

abstract = "Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.",

keywords = "Best practice, Direct acting antivirals, Drug-drug interactions, Hepatitis C virus, Opioid agonist therapy",

author = "Norton, {Brianna L.} and Akiyama, {Matthew J.} and Zamor, {Philippe J.} and Litwin, {Alain H.}",

note = "Funding Information: Disclosure: A.H. Litwin has served on the advisory board of Abbvie, BMS, Gilead Sciences, and Merck. P.J. Zamor has served on the speakers bureau for Gilead, AbbVie, Merck, and Bristol Myers Squibb, and on the advisory board for Gilead, AbbVie, and Bristol Myers Squibb. M.J. Akiyama has been the recipient of a Gilead Investigator Sponsored Research Grant. B.L. Norton has no conflicts of interest. This review was funded in part by NIDA K23DA039060, NIDA K24DA036955, and NIDA R01 DA034086.",

year = "2018",

month = jun,

doi = "10.1016/j.idc.2018.02.001",

language = "English (US)",

volume = "32",

pages = "347--370",

journal = "Infectious Disease Clinics of North America",

issn = "0891-5520",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy

T2 - A Review of Best Practice

AU - Norton, Brianna L.

AU - Akiyama, Matthew J.

AU - Zamor, Philippe J.

AU - Litwin, Alain H.

N1 - Funding Information: Disclosure: A.H. Litwin has served on the advisory board of Abbvie, BMS, Gilead Sciences, and Merck. P.J. Zamor has served on the speakers bureau for Gilead, AbbVie, Merck, and Bristol Myers Squibb, and on the advisory board for Gilead, AbbVie, and Bristol Myers Squibb. M.J. Akiyama has been the recipient of a Gilead Investigator Sponsored Research Grant. B.L. Norton has no conflicts of interest. This review was funded in part by NIDA K23DA039060, NIDA K24DA036955, and NIDA R01 DA034086.

PY - 2018/6

Y1 - 2018/6

N2 - Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.

AB - Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.

KW - Best practice

KW - Direct acting antivirals

KW - Drug-drug interactions

KW - Hepatitis C virus

KW - Opioid agonist therapy

UR - http://www.scopus.com/inward/record.url?scp=85047144147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047144147&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2018.02.001

DO - 10.1016/j.idc.2018.02.001

M3 - Review article

C2 - 29778260

AN - SCOPUS:85047144147

VL - 32

SP - 347

EP - 370

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2

ER -

Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this